Mazdutide 5mg

Important Note

This page is informational and does not authorize use. Peptify clients should complete assessment, disclose medications and health history, and follow the clinician-approved plan only.

Do not start, stop, combine, or change a protocol based only on website content.
Emergency symptoms require urgent medical care, not a website or routine follow-up message.

Quickstart Highlights

Mazdutide (IBI362 / LY3305677) is a long-acting dual GLP-1 and glucagon receptor agonist developed for chronic weight management and type-2-diabetes glycemic control[1][2]. Phase 2 and phase 3 trials have reported substantial weight loss (roughly 6–14% over 24–48 weeks) with mostly mild gastrointestinal side effects[2][3][5]. This educational page outlines a once-weekly subcutaneous approach with a dilution chosen so doses land on easy-to-read insulin-syringe marks. Mazdutide is approved in China (NMPA, June 2025) but is investigational and not FDA- or EMA-approved elsewhere — presented for research and educational use only.

Add 3.0 mL bacteriostatic water to one 5 mg vial → ~1.67 mg/mL (1,667 mcg/mL), the standard dilution for clear unit measurements.
2.5–6 mg once weekly with gradual stepwise titration; advanced research protocols may reach ~10 mg/week.
At ~1.67 mg/mL, 1 unit ≈ 16.7 mcg; 2.5 mg ≈ 150 units and 5 mg ≈ 300 units on a U-100 syringe.
Lyophilized: store at −20 °C (−4 °F); once reconstituted, refrigerate at 2–8 °C (35.6–46.4 °F) and do not freeze the solution.
Important: Start with the Prep & Injection Guide — it covers the preparation and safety basics every protocol on this site assumes.

Dosing & Reconstitution Guide

A practical dilution with accurate once-weekly dosing, step by step

Standard / Gradual Titration (3.0 mL = ~1.67 mg/mL)

Week(s)	Weekly Dose (mg)	Total Weekly Volume (U-100 units / mL)
Weeks 1–4	2.5 mg (2,500 mcg)	150 units (1.50 mL)
Weeks 5–8+	5 mg (5,000 mcg)	300 units (3.00 mL)

Reconstitute: Add 3.0 mL bacteriostatic water to one 5 mg vial → final concentration ~1.67 mg/mL (1,667 mcg/mL).
Typical weekly range: 2.5–6 mg once weekly, raised gradually with stepwise titration.
Easy measuring: At ~1.67 mg/mL, 1 unit ≈ 16.7 mcg on a U-100 syringe. The 2.5 mg maintenance dose reads at 150 units; a 5 mg dose reads at 300 units (full 3.0 mL).
Storage: Lyophilized: store at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and do not freeze the mixed solution.
Frequency: one subcutaneous injection once weekly, titrating up as tolerated. This stepwise schedule mirrors clinical-trial protocols designed to improve gastrointestinal tolerability[1][2]. A 5 mg dose fills the full 3.0 mL volume — if you prefer a smaller injection volume, use the higher-concentration advanced dilution below.

Reconstitution Steps

Draw 3.0 mL of bacteriostatic water into a sterile syringe.

Advanced / High-Dose Protocol (2.0 mL = 2.5 mg/mL)

Week(s)	Weekly Dose (mg)	Total Weekly Volume (U-100 units / mL)	Notes
Weeks 1–4	5 mg (5,000 mcg)	200 units (2.00 mL)	1 vial
Weeks 5–8	7.5 mg (7,500 mcg)	300 units (3.00 mL)	1.5 vials
Weeks 9–12+	10 mg (10,000 mcg)	400 units (4.00 mL)	2 vials; split into 2 injections

Release it slowly down the vial's inner wall to limit foaming.
Swirl or roll gently until fully dissolved — don't shake.
Label with the date and concentration, then refrigerate at 2–8 °C (35.6–46.4 °F), shielded from light.
Reconstituting with only 2.0 mL gives a higher concentration (2.5 mg/mL, so 1 unit = 25 mcg), reducing the injection volume for larger doses.
High-dose schedules (7.5–10 mg weekly) have only been explored in early-phase research and demand careful monitoring. Doses above ~6 mg increase the likelihood of gastrointestinal side effects. For any dose needing more than 3.0 mL of total volume, split it into two separate injections at different sites.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Supplies Needed

Quantities below assume an 8–16 week once-weekly course with gradual titration to a 5 mg maintenance dose.

A 5 mg vial covers about one week at the maintenance dose; titration uses less early on, so plan a little over one vial per maintenance week.
8 weeks: ~6 vials
12 weeks: ~10 vials
16 weeks: ~14 vials
One syringe per weekly injection; larger maintenance volumes may use a 3 mL syringe or be split.
Per injection: 1 syringe
8 weeks (once weekly): ~8 syringes
16 weeks (once weekly): ~16 syringes
Use ~3.0 mL per 5 mg vial for standard reconstitution.
8 weeks (6 vials): ~18 mL → 2 bottles
16 weeks (14 vials): ~42 mL → 5 bottles
One for the vial stopper + one for the injection site each week.
Per injection: 2 swabs
8–16 weeks (once weekly): ~16–32 swabs → 1 box

Protocol Overview

A concise summary of the once-weekly regimen, drawn from published clinical-trial protocols.

▪Goal: Support chronic weight management and glycemic control through dual GLP-1 / glucagon receptor activation[2][3].
▪Schedule: Once-weekly subcutaneous injections; trials have run from 12 to 48 weeks.
▪Dose Range: 2.5–6 mg weekly with gradual titration; advanced research protocols may reach ~10 mg.
▪Reconstitution: 3.0 mL per 5 mg vial gives ~1.67 mg/mL; use 2.0 mL for a higher concentration if needed.
▪Storage: Keep the dry vial frozen at −20 °C (−4 °F); once mixed, refrigerate at 2–8 °C and discard after ~28 days.

Dosing Protocol

A suggested weekly titration approach based on common clinical-trial reference doses.

▪Start: Begin at 2.5 mg once weekly for the first 4 weeks to establish tolerability.
▪Titrate: Step up to 5 mg weekly at week 5 and hold for the remainder of the protocol.
▪Target: Reach a 5–6 mg weekly maintenance dose; advanced research protocols may go higher.
▪Cycle Length: A minimum of ~8 weeks; clinical evidence supports 12–48 week courses.
▪Timing: Inject on the same day each week and rotate injection sites systematically.

Storage Instructions

Correct storage is what preserves the peptide's stability and activity.

▪Lyophilized: Hold the dry vial at −20 °C (−4 °F) in dry, dark conditions and limit moisture exposure[7].
▪Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F) and use within about 28 days; do not freeze the mixed solution, as freezing can denature peptides[7].
▪Handling: Let frozen vials warm to room temperature before opening so condensation won't form, and keep the solution clear of heat and direct light.
▪Discard: Dispose of reconstituted vials after 28 days or if cloudiness or particulates appear.

Important Notes

Practical points that keep weekly administration safe and consistent.

▪Sterile technique: Use a fresh sterile insulin syringe each week and drop it straight into a puncture-proof sharps container afterward.
▪Site rotation: Move between abdomen, thighs and upper arms each week to reduce local irritation and lipohypertrophy[8][10].
▪Split large volumes: For any dose needing more than ~3 mL of total volume, divide it into two injections at separate sites for comfort and absorption.
▪Warm before drawing: Let the reconstituted vial reach room temperature before withdrawing the dose to reduce viscosity.
▪Regulatory note: Mazdutide is approved in China for weight management and type-2 diabetes (NMPA, June 2025) but is investigational and not FDA- or EMA-approved elsewhere.

How This Works

Mazdutide (IBI362 / LY3305677) is a long-acting dual agonist that activates both the GLP-1 and the glucagon receptors[2][6]. The GLP-1 arm curbs appetite and slows gastric emptying, while the glucagon arm raises energy expenditure — together producing weight loss and improved glycemic control.

This dual mechanism distinguishes mazdutide from single-target GLP-1 agonists such as semaglutide. Phase 2 studies reported roughly 6.7–11.3% body-weight reduction at 3–6 mg weekly over 24 weeks[2], and a 48-week phase 3 trial described sustained weight loss of about 11–14% with 4–6 mg weekly maintenance[3].
In people with type 2 diabetes, mazdutide achieved meaningful HbA1c reductions (around 1.7%) alongside roughly 7% weight loss[4]. Its extended half-life enables convenient once-weekly dosing with steady pharmacologic exposure.
Approval status: China's NMPA approved mazdutide in June 2025 for chronic weight management and for glycemic control in type 2 diabetes. Outside China it remains investigational and is not FDA- or EMA-approved; the dosing here is presented for research and educational purposes only.

Lifestyle Factors

Habits that may support outcomes alongside the protocol.

▪Nutrition: Keep a balanced, nutrient-dense diet with adequate protein to preserve lean mass during weight loss.
▪Activity & rest: Combine resistance training with aerobic exercise to protect muscle and support metabolic adaptation.
▪Sleep: Aim for 7–9 hours to support adherence and hormonal balance.
▪Hydration & electrolytes: Stay well hydrated and watch electrolyte intake, especially during early titration when GI effects are more likely.

Potential Benefits & Side Effects

Observations drawn from clinical-trial evidence; individual results vary.

▪Significant weight loss: 6–14% body-weight reduction over 24–48 weeks in obesity trials[2][3][5].
▪Glycemic improvement: Meaningful HbA1c reductions (~1.7%) in type-2-diabetes populations[4].
▪Metabolic effects: Reported improvements in lipid profiles and glucose control alongside weight loss.
▪Convenient dosing: Once-weekly administration can improve adherence versus daily regimens.
▪Gastrointestinal effects: Nausea, vomiting, diarrhea and constipation are most common — usually mild to moderate and easing with continued use[5].
▪Injection-site reactions: Mild redness, swelling or discomfort can occur; rotating sites helps.
▪Titration matters: Gradual dose escalation improves tolerability and reduces discontinuation[1][2].

Injection Technique

General subcutaneous technique, following established clinical best-practice guidance[8][10].

▪Wash your hands well with soap and water.
▪Wipe the vial stopper with an alcohol swab and let it air-dry.
▪Choose a site (abdomen, thigh, or upper arm) and clean it with a fresh alcohol swab, letting it dry fully.
▪Draw the intended dose, then check for air bubbles and push any out.
▪Pinch a skinfold at the chosen site between thumb and forefinger.
▪Insert the needle into the pinch at a 45–90-degree angle (use 45 degrees if the fat layer is thin)[8].
▪Skip aspiration for subcutaneous shots — it isn't needed[8].
▪Press the plunger slowly and steadily until it's fully down.
▪Wait 5–10 seconds, then pull the needle straight out to prevent leakage.
▪Drop the used syringe straight into a puncture-proof sharps container — never recap a needle.
▪Return the reconstituted vial to the fridge right away.
▪Rotate the injection site each week to prevent irritation and lipohypertrophy[8].
▪Watch the site for excess redness, swelling, or signs of infection.

Recommended Source

For high-purity research peptides, we point researchers to Prime Lab Peptides for Mazdutide (5 mg).

▪Top-rated on Trustpilot: Independently reviewed as the highest-rated peptide lab on Trustpilot — making it the best current source in the USA. Open source
▪Third-party tested: Every batch ships with a Certificate of Analysis (COA) confirming purity and composition.
▪Consistent quality: ISO-aligned manufacturing and handling keep product integrity reliable batch to batch.
▪Cold-chain integrity: Temperature-controlled shipping and storage across the whole fulfilment chain.
▪Research-grade purity: Fit for educational and research use that demands high-quality peptides.
Note: Product availability and specifications subject to change. Verify current product details on supplier website.
Shop at Prime Lab Peptides →

References

Reference-derived details for Mazdutide 5mg.

Mazdutide (5mg Vial) Dosage Protocol Open source
1 EClinicalMedicine (PubMed) Phase 1b trial: safety and efficacy of mazdutide 9–10 mg in Chinese adults with overweight or obesity. View Source ↗ Open source
2 Nature Communications Phase 2 randomized controlled trial of mazdutide in Chinese adults with overweight or obesity. View Source ↗ Open source
3 New England Journal of Medicine Phase 3 trial: once-weekly mazdutide in Chinese adults with obesity or overweight (48-week results). View Source ↗ Open source
4 Diabetes Care (PubMed) Phase 2 trial: efficacy and safety of mazdutide in Chinese patients with type 2 diabetes. View Source ↗ Open source
5 Frontiers in Endocrinology Systematic review and meta-analysis of mazdutide for weight loss in diabetic and non-diabetic patients. View Source ↗ Open source
6 International Journal of Obesity (Nature) Review of the pipeline for future obesity medications, including GLP-1 / glucagon dual agonists such as mazdutide. View Source ↗ Open source
7 Bachem Peptide Technical Guide Handling and storage guidelines for peptides, both lyophilized and in solution. View Source ↗ Open source
8 NCBI Bookshelf Best practices for subcutaneous injection: aseptic technique and site rotation. View Source ↗ Open source
9 NMPA / China Regulatory Notice China NMPA approval of mazdutide (June 2025) for chronic weight management and type-2-diabetes glycemic control. View Source ↗ Open source
10 CDC Subcutaneous injection technique: angle, site selection and no-aspiration guidance. View Source ↗ Open source

Contents